The article “Contemporary Management of Atrial Fibrillation,” written by Leslie L. Davis, Guest Editor of the November/December 2013 issue, contained an error. On page 645, this sentence should have read, “Likewise, patients who are on a newer antithrombotic agent (dabigatran [Pradaxa®], rivaroxaban [Xarelto®], and apixaban [Eliquis®]) should also start taking these medications for at least 30 days before the attempt to restore sinus rhythm by chemical or DCCV.”
Article info
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Contemporary Management of Atrial FibrillationThe Journal for Nurse PractitionersVol. 9Issue 10
- PreviewNurse practitioners (NPs) frequently treat adults with atrial fibrillation. With new oral antithrombotic agents available, NPs need to be knowledgeable of treatment options to prevent stroke and systemic emboli. This article reviews the latest American College of Cardiology Foundation/American Heart Association guideline on the management of atrial fibrillation. Emphasis is placed on the changing landscape of pharmacological agents. Use of guideline-directed medical therapy will ultimately improve patients’ quality of life and prevent stroke and premature death.
- Full-Text
- Preview
